295 related articles for article (PubMed ID: 17243162)
1. Amplification and translocation of 3q26 with overexpression of EVI1 in Fanconi anemia-derived childhood acute myeloid leukemia with biallelic FANCD1/BRCA2 disruption.
Meyer S; Fergusson WD; Whetton AD; Moreira-Leite F; Pepper SD; Miller C; Saunders EK; White DJ; Will AM; Eden T; Ikeda H; Ullmann R; Tuerkmen S; Gerlach A; Klopocki E; Tönnies H
Genes Chromosomes Cancer; 2007 Apr; 46(4):359-72. PubMed ID: 17243162
[TBL] [Abstract][Full Text] [Related]
2. A novel chromosomal translocation t(3;7)(q26;q21) in myeloid leukemia resulting in overexpression of EVI1.
Storlazzi CT; Anelli L; Albano F; Zagaria A; Ventura M; Rocchi M; Panagopoulos I; Pannunzio A; Ottaviani E; Liso V; Specchia G
Ann Hematol; 2004 Feb; 83(2):78-83. PubMed ID: 14551738
[TBL] [Abstract][Full Text] [Related]
3. Three novel cytogenetically cryptic EVI1 rearrangements associated with increased EVI1 expression and poor prognosis identified in 27 acute myeloid leukemia cases.
Haferlach C; Bacher U; Grossmann V; Schindela S; Zenger M; Kohlmann A; Kern W; Haferlach T; Schnittger S
Genes Chromosomes Cancer; 2012 Dec; 51(12):1079-85. PubMed ID: 22887804
[TBL] [Abstract][Full Text] [Related]
4. EVI1 overexpression in distinct subtypes of pediatric acute myeloid leukemia.
Balgobind BV; Lugthart S; Hollink IH; Arentsen-Peters ST; van Wering ER; de Graaf SS; Reinhardt D; Creutzig U; Kaspers GJ; de Bont ES; Stary J; Trka J; Zimmermann M; Beverloo HB; Pieters R; Delwel R; Zwaan CM; van den Heuvel-Eibrink MM
Leukemia; 2010 May; 24(5):942-9. PubMed ID: 20357826
[TBL] [Abstract][Full Text] [Related]
5. An interphase fluorescence in situ hybridisation assay for the detection of 3q26.2/EVI1 rearrangements in myeloid malignancies.
Bobadilla D; Enriquez EL; Alvarez G; Gaytan P; Smith D; Slovak ML
Br J Haematol; 2007 Mar; 136(6):806-13. PubMed ID: 17341266
[TBL] [Abstract][Full Text] [Related]
6. Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer.
Nanjundan M; Nakayama Y; Cheng KW; Lahad J; Liu J; Lu K; Kuo WL; Smith-McCune K; Fishman D; Gray JW; Mills GB
Cancer Res; 2007 Apr; 67(7):3074-84. PubMed ID: 17409414
[TBL] [Abstract][Full Text] [Related]
7. Acute panmyelosis with myelofibrosis with EVI1 amplification.
Grygalewicz B; Woroniecka R; Pastwińska A; Rygier J; Krawczyk P; Borg K; Makuch-Łasica H; Patkowska E; Pieńkowska-Grela B
Cancer Genet; 2012 May; 205(5):255-60. PubMed ID: 22682625
[TBL] [Abstract][Full Text] [Related]
8. Fluorescence in situ hybridization studies using BAC clones of the EVI1 locus in hematological malignancies with 3q rearrangements.
Madrigal I; Carrió A; Gómez C; Rozman M; Esteve J; Nomdedeu B; Campo E; Costa D
Cancer Genet Cytogenet; 2006 Oct; 170(2):115-20. PubMed ID: 17011981
[TBL] [Abstract][Full Text] [Related]
9. A cross-linker-sensitive myeloid leukemia cell line from a 2-year-old boy with severe Fanconi anemia and biallelic FANCD1/BRCA2 mutations.
Meyer S; Fergusson WD; Oostra AB; Medhurst AL; Waisfisz Q; de Winter JP; Chen F; Carr TF; Clayton-Smith J; Clancy T; Green M; Barber L; Eden OB; Will AM; Joenje H; Taylor GM
Genes Chromosomes Cancer; 2005 Apr; 42(4):404-15. PubMed ID: 15645491
[TBL] [Abstract][Full Text] [Related]
10. EVI1 overexpression in t(3;17) positive myeloid malignancies results from juxtaposition of EVI1 to the MSI2 locus at 17q22.
De Weer A; Speleman F; Cauwelier B; Van Roy N; Yigit N; Verhasselt B; De Moerloose B; Benoit Y; Noens L; Selleslag D; Lippert E; Struski S; Bastard C; De Paepe A; Vandenberghe P; Hagemeijer A; Dastugue N; Poppe B;
Haematologica; 2008 Dec; 93(12):1903-7. PubMed ID: 18815193
[TBL] [Abstract][Full Text] [Related]
11. The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias.
Lo Coco F; Pisegna S; Diverio D
Haematologica; 1997; 82(3):364-70. PubMed ID: 9234595
[TBL] [Abstract][Full Text] [Related]
12. EVI1 is consistently expressed as principal transcript in common and rare recurrent 3q26 rearrangements.
Poppe B; Dastugue N; Vandesompele J; Cauwelier B; De Smet B; Yigit N; De Paepe A; Cervera J; Recher C; De Mas V; Hagemeijer A; Speleman F
Genes Chromosomes Cancer; 2006 Apr; 45(4):349-56. PubMed ID: 16342172
[TBL] [Abstract][Full Text] [Related]
13. High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities.
Gröschel S; Lugthart S; Schlenk RF; Valk PJ; Eiwen K; Goudswaard C; van Putten WJ; Kayser S; Verdonck LF; Lübbert M; Ossenkoppele GJ; Germing U; Schmidt-Wolf I; Schlegelberger B; Krauter J; Ganser A; Döhner H; Löwenberg B; Döhner K; Delwel R
J Clin Oncol; 2010 Apr; 28(12):2101-7. PubMed ID: 20308656
[TBL] [Abstract][Full Text] [Related]
14. Genetic reversion in an acute myelogenous leukemia cell line from a Fanconi anemia patient with biallelic mutations in BRCA2.
Ikeda H; Matsushita M; Waisfisz Q; Kinoshita A; Oostra AB; Nieuwint AW; De Winter JP; Hoatlin ME; Kawai Y; Sasaki MS; D'Andrea AD; Kawakami Y; Joenje H
Cancer Res; 2003 May; 63(10):2688-94. PubMed ID: 12750298
[TBL] [Abstract][Full Text] [Related]
15. Ecotropic virus integration site-1 gene preferentially expressed in post-myelodysplasia acute myeloid leukemia: possible association with GATA-1, GATA-2, and stem cell leukemia gene expression.
Ohyashiki JH; Ohyashiki K; Shimamoto T; Kawakubo K; Fujimura T; Nakazawa S; Toyama K
Blood; 1995 Jun; 85(12):3713-8. PubMed ID: 7780155
[TBL] [Abstract][Full Text] [Related]
16. Conventional cytogenetics and breakpoint distribution by fluorescent in situ hybridization in patients with malignant hemopathies associated with inv(3)(q21;q26) and t(3;3)(q21;q26).
De Braekeleer E; Douet-Guilbert N; Basinko A; Bovo C; Guéganic N; Le Bris MJ; Morel F; De Braekeleer M
Anticancer Res; 2011 Oct; 31(10):3441-8. PubMed ID: 21965759
[TBL] [Abstract][Full Text] [Related]
17. Acute myeloid leukemia (AML) with t(8;21)(q22;q22) relapsing as AML with t(3;21)(q26;q22).
Bacher U; Schnittger S; Kern W; Trenn G; Weisser M; Haferlach T; Schoch C
Cancer Genet Cytogenet; 2006 Jul; 168(2):172-4. PubMed ID: 16843110
[TBL] [Abstract][Full Text] [Related]
18. Quantitative comparison of the expression of EVI1 and its presumptive antagonist, MDS1/EVI1, in patients with myeloid leukemia.
Vinatzer U; Mannhalter C; Mitterbauer M; Gruener H; Greinix H; Schmidt HH; Fonatsch C; Wieser R
Genes Chromosomes Cancer; 2003 Jan; 36(1):80-9. PubMed ID: 12461752
[TBL] [Abstract][Full Text] [Related]
19. Complex chromosomal rearrangements leading to MECOM overexpression are recurrent in myeloid malignancies with various 3q abnormalities.
Baldazzi C; Luatti S; Zuffa E; Papayannidis C; Ottaviani E; Marzocchi G; Ameli G; Bardi MA; Bonaldi L; Paolini R; Gurrieri C; Rigolin GM; Cuneo A; Martinelli G; Cavo M; Testoni N
Genes Chromosomes Cancer; 2016 Apr; 55(4):375-88. PubMed ID: 26815134
[TBL] [Abstract][Full Text] [Related]
20. Amplification of EVI1 on cytogenetically cryptic double minutes as new mechanism for increased expression of EVI1.
Volkert S; Schnittger S; Zenger M; Kern W; Haferlach T; Haferlach C
Cancer Genet; 2014 Mar; 207(3):103-8. PubMed ID: 24726268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
